Correspondence re: A. S. Lübbe et al., Preclinical Experiences with Magnetic Drug Targeting: Tolerance and Efficacy. Cancer Res., 56: 4694–4701, 1996; and Clinical Experiences with Magnetic Drug Targeting: A Phase I Study with 4′-Epidoxorubicin in 14 Patients with Advanced Solid Tumors. Cancer Res., 56: 4686–4693, 1996—Reply
Cancer Res (1997) 57 (14): 3064–3065.
Currently there are no citedby results. Try again later.